Fulgent Genetics opened lower at $25.41, compared with its previous close of $25.70. In the last trading session, the stock traded between $24.55 and $25.73. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Fulgent Genetics is now worth
$ 29.08
Resulting in a loss of
$ 70.92 (70.92%)
Invest with $1
Note: Past profits do not guarantee future returns.
Piper Sandler raised Fulgent Genetics' price target to $25. The previous price target was set at $19. Analyst David Westenberg maintained a Neutral rating.
2 days ago
6Nov
Fulgent Genetics Q3 revenue up 8% to $90.4M; FY26 adj EPS guidance raised
Q3 revenue rose 8% YoY to $90.4 million, driven by Vocal Diagnostics and STRADA Dx integration. FY26 adjusted EPS guidance raised to $(1.75) to $(1.65), beating consensus estimate of $(2.27). Cash position increased to $652.4 million, aided by a $112.3 million federal tax refund. Non-GAAP operating margin improved sequentially to -13.2% from -26.2% in Q2.
7 days ago
16Oct
Fulgent Genetics Q3FY26 Results: Release date set for November 5
Fulgent Genetics to release Q3FY26 financial results on November 5, 2026. Conference call scheduled for 4:30 pm ET on the same day. Company operates in laboratory services and therapeutic development sectors.
Fulgent Genetics reported Q2 2026 revenue of $85.4 million and a non-GAAP loss of $16.2 million. Management lowered full-year revenue guidance to $330-$340 million citing billing system transition delays, while maintaining a strong cash position of $551.5 million.
3mo ago
31Jul
Fulgent Genetics Latest Results: Cuts FY26 EPS Guidance to Loss
Fulgent Genetics lowers FY2026 adjusted EPS guidance to a loss of $2.35-$2.22, missing the $(1.55) analyst estimate. Revenue guidance is also cut to $330-$340 million, below the $351.9 million consensus.
3mo ago
10Jul
Fulgent Genetics to announce Q2 2026 results on July 30
Fulgent Genetics will announce its Q2 2026 financial results on July 30, 2026, followed by a conference call at 4:30 PM ET. The company operates in laboratory services and therapeutic development, targeting precision medicine integration.
